window.pageData = {"stock":{"_id":3000000025749,"name":"招商医药量化选股混合型发起式证券投资基金","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","status":"normal","stockCode":"025749","tickerId":25749,"shortName":"招商医药量化选股混合发起式C","currency":"CNY","exchange":"jj","masterFundFlag":null,"indexFundFlag":null,"activeFundFlag":null,"etfFundFlag":null,"lofFundFlag":null,"pensionTargetFlag":null,"feederFundFlag":null,"classificationFlag":null,"closedEnd":null,"inceptionDate":"2026-01-22T16:00:00.000Z","pinyin":"zsyylhxghhxfqszqtzjj","fundCollectionId":4000050210000,"followedNum":1,"fundCollection":{"exchange":"jjgs","stockType":"fund_collection","stockCode":"50210000","tickerId":50210000,"name":"招商基金管理有限公司"},"managers":[{"name":"文雨","stockType":"fund_manager","stockCode":"j101020192","exchange":"fm","tickerId":2325256800}],"hotMetrics":{"fpr":{"stockId":3000000025749,"type":"fpr","f_cagr_p_r_fs_ssc":9176,"f_cagr_p_r_fs_ssrp":0.9455040871934605,"f_p_r_m1_ssc":9231,"f_p_r_m1_ssrp":0.8241603466955579,"f_p_r_m3_ssc":9128,"f_p_r_m3_ssrp":0.8008107811986414},"fp":{"stockId":3000000025749,"type":"fp","last_data_date":"2026-05-20T16:00:00.000Z","f_cagr_p_r_fs":-0.06403596403596379,"f_p_r_m1":-0.03640851589015748,"f_p_r_m3":-0.05037502533954996},"f_nlacan":{"stockId":3000000025749,"type":"f_nlacan","f_nv_d":"2026-05-20T16:00:00.000Z","f_nv":0.9369,"f_nv_cr":0.0010684902233144555},"f_as":{"stockId":3000000025749,"type":"f_as","f_tas":30973934.5157,"f_tas_d":"2026-03-30T16:00:00.000Z"}},"masterSlaveFunds":[{"_id":3000000025748,"__csrcFundId":16251,"stockCode":"025748","masterFundShortName":"招商医药量化选股混合发起式","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":25748,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"招商医药量化选股混合发起式(025748)","lastUpdated":"2026-05-01T04:50:55.524Z","name":"招商医药量化选股混合型发起式证券投资基金","pinyin":"zsyylhxghhxfqszqtzjj","fundCollectionId":4000050210000,"followedNum":5,"setUpAssetScale":127553582.52,"setUpDate":"2026-01-19T16:00:00.000Z","setUpShares":127553582.52,"inceptionDate":"2026-01-22T16:00:00.000Z"}],"shareholdings":[{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000025748,"stockId":603259,"holdings":106500,"marketCap":10447650,"netValueRatio":0.0724,"quarterlyChange":0.08230361871138547,"stock":{"stockCode":"603259","exchange":"sh","stockType":"company","tickerId":603259,"name":"药明康德"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000025748,"stockId":600276,"holdings":166100,"marketCap":9172042,"netValueRatio":0.0635,"quarterlyChange":-0.07302333389289883,"stock":{"stockCode":"600276","exchange":"sh","stockType":"company","tickerId":600276,"name":"恒瑞医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000025748,"stockId":300760,"holdings":22874,"marketCap":3766432,"netValueRatio":0.0261,"quarterlyChange":-0.13541611971646128,"stock":{"stockCode":"300760","exchange":"sz","stockType":"company","tickerId":300760,"name":"迈瑞医疗"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000025748,"stockId":688271,"holdings":29673,"marketCap":3323376,"netValueRatio":0.023,"quarterlyChange":-0.10756972111553775,"stock":{"name":"联影医疗","exchange":"sh","stockType":"company","stockCode":"688271","tickerId":688271}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000025748,"stockId":963,"holdings":82700,"marketCap":2920964,"netValueRatio":0.0202,"quarterlyChange":-0.1046894803548798,"stock":{"stockCode":"000963","exchange":"sz","stockType":"company","tickerId":963,"name":"华东医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000025748,"stockId":300759,"holdings":102800,"marketCap":2876344,"netValueRatio":0.0199,"quarterlyChange":-0.015828350334153862,"stock":{"stockCode":"300759","exchange":"sz","stockType":"company","tickerId":300759,"name":"康龙化成"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000025748,"stockId":300347,"holdings":50500,"marketCap":2718415,"netValueRatio":0.0188,"quarterlyChange":-0.050617283950616376,"stock":{"stockCode":"300347","exchange":"sz","stockType":"company","tickerId":300347,"name":"泰格医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000025748,"stockId":2821,"holdings":23500,"marketCap":2603095,"netValueRatio":0.018,"quarterlyChange":0.19197245238351623,"stock":{"stockCode":"002821","exchange":"sz","stockType":"company","tickerId":2821,"name":"凯莱英"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000025748,"stockId":600196,"holdings":95800,"marketCap":2551154,"netValueRatio":0.0177,"quarterlyChange":0.005285013212534162,"stock":{"stockCode":"600196","exchange":"sh","stockType":"company","tickerId":600196,"name":"复星医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000025748,"stockId":688235,"holdings":9761,"marketCap":2280071,"netValueRatio":0.0158,"quarterlyChange":-0.1303425167535377,"stock":{"stockCode":"688235","tickerId":688235,"exchange":"sh","stockType":"company","name":"百济神州"}}]},"list":[{"_id":"69e8ecbd1398d79843fea17b","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","stockId":3000000025748,"sao":"报告期内，A股市场整体呈现震荡格局，结构性机会显著。全指医药卫生指数经历调整后于季末反弹，季度累计下跌0.77%。板块内部分化剧烈，创新药及产业链成为贯穿一季度的核心主线，尤其在3月中下旬走出独立行情，大幅跑赢市场。驱动因素明确：一是出海爆发式增长，一季度中国创新药对外授权交易总额取得明显突破，验证了中国创新资产的全球价值；二是业绩高增长验证，创新药龙头公司2025年年报业绩亮眼，为板块提供了坚实的基本面支撑；三是密集事件催化，欧洲肺癌大会召开，且市场对美国癌症研究协会年会等后续国际学术会议充满期待。此外，医疗服务、化学制药子行业在季度末表现强势。政策方面，2026年政府工作报告明确提出“推动创新药和医疗器械高质量发展”，并将医药生物定位为与集成电路、航空航天并列的“新兴支柱产业”，强调打造全球竞争力。这为行业长期发展奠定了积极的政策基调。展望2026年第二季度，我们认为医药板块在经历一季度的充分调整与季末反弹后，行情有望从超跌反弹转向基本面驱动下的分化与精选。积极因素正在累积：首先，产业趋势强劲。创新药出海已进入规模化、高价值的新阶段，国际化能力成为核心估值锚。其次，政策支持方向清晰且力度加大。医药生物被定位为“新兴支柱产业”，预计后续配套支持政策将陆续出台。此外，事件催化密集，4月的AACR全球肿瘤年会、5月的ASCO年会等将披露大量前沿临床数据，可能持续催生新的投资机会。然而，也需要关注潜在风险：一是估值与业绩的匹配度。经过季末反弹，部分赛道估值已有所修复，需要后续业绩持续高增长来消化。二是行业内部竞争加剧。同质化研发可能导致部分领域内卷，影响企业盈利天花板。三是全球流动性及地缘政治风险，可能对生物科技这类风险偏好较高的资产造成阶段性冲击。综合而言，医药行业长期受益于人口老龄化、消费升级和技术进步，具备穿越周期的属性。二季度，我们将更加注重自下而上的个股选择，在创新药、医疗器械、消费医疗等长期优质赛道中，寻找估值与成长性匹配、业绩确定性高的标的。本基金将继续在控制跟踪误差的基础上，通过深入的基本面研究与科学的量化模型，努力为投资者创造持续的超额回报。","lastUpdated":"2026-04-22T15:43:57.436Z","fund":{"_id":3000000025748,"__csrcFundId":16251,"stockCode":"025748","masterFundShortName":"招商医药量化选股混合发起式","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":25748,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"招商医药量化选股混合发起式(025748)","lastUpdated":"2026-05-01T04:50:55.524Z","name":"招商医药量化选股混合型发起式证券投资基金","pinyin":"zsyylhxghhxfqszqtzjj","fundCollectionId":4000050210000,"followedNum":5,"setUpAssetScale":127553582.52,"setUpDate":"2026-01-19T16:00:00.000Z","setUpShares":127553582.52,"inceptionDate":"2026-01-22T16:00:00.000Z","managers":[{"stockCode":"j101020192","stockType":"fund_manager","exchange":"fm","tickerId":2325256800,"name":"文雨"}]},"announcement":{"linkText":"招商医药量化选股混合型发起式证券投资基金2026年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1474943","linkType":"PDF","source":"csrc_pdf"}}]}